I am a
Home I AM A Search Login

Papers of the Week

2022 Nov

JGH Open



A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.


Chen C-Y, Chuang W-L, Qin A, Zhang W-H, Zhu L-Y, Zhang G-Q, Chen J-J, Lo C-C, Zhou X, Mao X, Shang J, Kuo H-T, Xie W, Chen C-H, Lo G-H, Jun DW, Dang S, Tsai C-Y, Wang T-F, Lai H-H, et al.
JGH Open. 2022 Nov; 6(11):782-791.
PMID: 36406648.


Ropeginterferon alfa-2b is a novel mono-pegylated, extra-long-acting interferon. It is administered infrequently and showed good tolerability and clinical activity for the chronic hepatitis B or C treatment in our previous Phase 2 clinical trials. This study aims to validate the potency and safety of this novel agent in a Phase 3 chronic viral hepatitis setting.